疏凿饮子加减治疗慢性肾小球肾炎的临床研究Δ.

OBJECTIVE: To probe into the clinical efficacy of modified Shuzao Yinzi in the treatment of chronic glomerulonephritis from the perspective of “ real” diagnosis and treatment. METHODS: A total of 92 patients with chronic glomerulonephritis admitted into hospital from Jan. 2020 to Apr. 2022 were selected and randomly divided into control group and treatment group via random number table method, with 46 cases in each group. The control group was given Benazepril hydrochloride tablets, while the treatment group was given modified Shuzao Yinzi based on the control group. The clinical efficacy, TCM syndrome score, renal function level [blood urea nitrogen (BUN), serum creatinine (SCr), 24 h urine protein quantitation and glomerular filtration rate], routine urine examination [ white blood cell count and red blood cell count in urine] and renal hemodynamic indicators [ peak systolic flow velocity (PSFV), end-diastolic blood flow velocity (EDFV), pulsatility index (PI), resistance index (RI)] of both groups were observed before and after treatment. RESULTS: After treatment, the total effective rate of the treatment group was 93. 48% (43 / 46), which was significantly higher than that of the control group (78. 26%, 36 / 46), with statistically significant difference (P<0. 05). After treatment, the scores of facial and limb edema, lower back stabbing pain, swollen sore throat, indigestion and loss of appetite in both groups were significantly lower than those before treatment, and those of the treatment group were lower than the control group; after treatment, the BUN, SCr and 24 h urine protein quantitation in both groups were lower than those before treatment, the glomerular filtration rate was higher than that before treatment, and those of the treatment group were better than the control group; after treatment, the white blood cell count and red blood cell count in urine in both groups were lower than those before treatment, and those of the treatment group were better than the control group; after treatment, the PSFV and EDFV values in both groups were higher than those before treatment, the PI and RI values were lower than those before treatment, and those of the treatment group were better than the control group, with statistically significant differences (P < 0. 05). CONCLUSIONS: The efficacy of modified Shuzao Yinzi in the treatment of chronic glomerulonephritis is remarkable. [ABSTRACT FROM AUTHOR]